This is an international site for Exjade® (Deferasirox) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional I am a patient inside of the US I am a patient outside the U.S.

Home > Lower-risk Myelodysplastic Syndrome > Overview
Print
Myelodysplastic Syndromes

In transfusion-dependent, lower-risk
myelodysplastic syndrome

Iron Chelation Is an
Important Part of
Overall Supportive
Care Management

Patients with lower-risk MDS are living significantly longer due to improved care, including red blood cell transfusions—the mainstay of treatment for most. These advancements extend the lives of lower-risk transfusion-dependent MDS patients to a median of 3.5 to 5.7 years, but it also puts them at risk for iron toxicity.1,2,3

Survival Rates by IPSS Classification

Patients like these need effective chelation that does not overburden their already complicated treatment regimen. Once-daily oral EXJADE may be the appropriate chelation treatment for these patients.1

EXJADE reduces the burden of iron toxicity

EXJADE clinical studies show reductions in serum ferritin and liver iron concentration. With an established safety profile, EXJADE offers tailored dosing to meet the needs of your patients.

Learn more about EXJADE efficacy
Learn more about EXJADE dosing
Learn more about EXJADE safety profile

References

  1. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes [Critical Review]. Am J Hematol. 2008;83:858-861.
  2. Greenberg PL. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2002:136-161.
  3. Malcovati L, Porta MGD, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594-7603.

SEE THE RISKS ASSOCIATED WITH IRON TOXICITY

Patients with lower-risk MDS
who receive transfusions that
extend their survival
time face serious
consequences from
their transfusion
therapy.

Learn more

IDENTIFY THE RISK LEVEL OF YOUR MDS PATIENTS

Both the International Prognostic
Scoring System and the World
Health Organization guidelines
can be used to identify the
risk level of patients with
myelodysplastic syndrome.

TRANSFUSION-DEPENDENT
β-THALASSEMIA		 MYELODYSPLASTIC SYNDROMES SICKLE CELL DISEASE APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with β-thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusion in patients aged 2 years and older with β-thalassemia major or other anemias when deferoxamine is contraindicated or inadequate.
Disclaimer: This is an international website for Exjade, and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© Novartis AG | Use of this website is subject to our Terms of Use | About Novartis Oncology | Privacy | Site Map | Contact Us | EU SmPC | Safety Information | PubMed